# Zoledronic Acid in MS-patients With Osteoporosis

> **NCT01166178** · PHASE3 · TERMINATED · sponsor: **Novartis** · enrollment: 29 (actual)

## Conditions studied

- Osteoporosis
- Multiple Sclerosis

## Interventions

- **DRUG:** Zoledronic Acid
- **DRUG:** Placebo
- **DIETARY_SUPPLEMENT:** Calcium and Vitamin D combination

## Key facts

- **NCT ID:** NCT01166178
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2013-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01166178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01166178, "Zoledronic Acid in MS-patients With Osteoporosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01166178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*